Northern Trust’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-372,733
| Closed | -$593K | – | 4521 |
|
|
2024
Q1 | $593K | Buy |
372,733
+35,451
| +11% | +$56.4K | ﹤0.01% | 3509 |
|
|
2023
Q4 | $290K | Sell |
337,282
-6,789
| -2% | -$5.83K | ﹤0.01% | 3739 |
|
|
2023
Q3 | $368K | Sell |
344,071
-8,979
| -3% | -$9.61K | ﹤0.01% | 3598 |
|
|
2023
Q2 | $914K | Sell |
353,050
-972
| -0.3% | -$2.52K | ﹤0.01% | 3393 |
|
|
2023
Q1 | $1.44M | Buy |
354,022
+9,343
| +3% | +$38.1K | ﹤0.01% | 3087 |
|
|
2022
Q4 | $1.73M | Buy |
344,679
+5,608
| +2% | +$28.2K | ﹤0.01% | 3072 |
|
|
2022
Q3 | $4.43M | Sell |
339,071
-2,180
| -0.6% | -$28.5K | ﹤0.01% | 2562 |
|
|
2022
Q2 | $4.38M | Buy |
341,251
+48,145
| +16% | +$617K | ﹤0.01% | 2606 |
|
|
2022
Q1 | $4.47M | Sell |
293,106
-11,408
| -4% | -$174K | ﹤0.01% | 2644 |
|
|
2021
Q4 | $5.39M | Buy |
304,514
+5,054
| +2% | +$89.5K | ﹤0.01% | 2631 |
|
|
2021
Q3 | $6.3M | Buy |
299,460
+2,020
| +0.7% | +$42.5K | ﹤0.01% | 2593 |
|
|
2021
Q2 | $5.87M | Buy |
297,440
+23,600
| +9% | +$465K | ﹤0.01% | 2742 |
|
|
2021
Q1 | $7.96M | Buy |
273,840
+4,368
| +2% | +$127K | ﹤0.01% | 2449 |
|
|
2020
Q4 | $8.16M | Sell |
269,472
-6,224
| -2% | -$189K | ﹤0.01% | 2383 |
|
|
2020
Q3 | $4.39M | Buy |
275,696
+14,057
| +5% | +$224K | ﹤0.01% | 2627 |
|
|
2020
Q2 | $5.17M | Sell |
261,639
-2,763
| -1% | -$54.5K | ﹤0.01% | 2501 |
|
|
2020
Q1 | $3.26M | Buy |
264,402
+2,163
| +0.8% | +$26.7K | ﹤0.01% | 2563 |
|
|
2019
Q4 | $4.85M | Buy |
262,239
+161,028
| +159% | +$2.98M | ﹤0.01% | 2599 |
|
|
2019
Q3 | $1.4M | Buy |
101,211
+55,145
| +120% | +$763K | ﹤0.01% | 3272 |
|
|
2019
Q2 | $675K | Buy |
+46,066
| New | +$675K | ﹤0.01% | 3476 |
|